IVD 감염병 시장 규모 : 제품 유형별, 용도별, 최종 사용자별, 지역별, 예측별, 예측별

Global IVD Infectious Diseases Market Overview

The IVD infectious diseases market is expanding steadily as hospitals, diagnostic laboratories, and research institutes increase testing for viral, bacterial, and parasitic infections. Advanced diagnostic tools, including molecular assays, immunoassays, and rapid tests, enable early and accurate detection of infectious agents such as influenza, COVID-19, hepatitis, and HIV. These tests support timely treatment decisions, infection control, and disease monitoring, strengthening healthcare outcomes across clinical and public health settings.

Market growth is supported by continuous improvements in diagnostic technologies, laboratory automation, and point-of-care testing platforms. The increasing prevalence of infectious diseases, expansion of healthcare infrastructure, and rising public health initiatives are driving adoption of innovative IVD solutions. Additionally, growing awareness of early disease detection, integration with digital reporting systems, and demand for high-throughput testing capabilities are encouraging hospitals, laboratories, and research organizations to adopt advanced diagnostic tools, further expanding the market globally.

Market size -VMR Analyst Corridor Approach

A revenue convergence corridor is emerging across recent global assessments instead of relying on a single-point estimate. Market value is consolidating around USD 15.8 Billion in 2025, while long-term projections are extending toward USD 21.9 Billion by 2033, reflecting mid- to high-single-digit growth momentum. A CAGR of 4.15% is being recorded over the forecast period (2027-2033), underscoring the market's structurally resilient growth trajectory

Global IVD Infectious Diseases Market Definition

The IVD infectious diseases market refers to the healthcare ecosystem focused on detecting and diagnosing infections caused by viruses, bacteria, and parasites using in vitro diagnostic tools. The market includes molecular assays, immunoassays, rapid diagnostic kits, point-of-care testing devices, and automated laboratory analyzers used by hospitals, diagnostic laboratories, and research institutes. These tools identify pathogens, measure infection markers, and provide critical data to support patient diagnosis, treatment, and infection control.

Market activity involves diagnostic device manufacturers, biotechnology companies, clinical laboratories, and research organizations collaborating to develop and supply testing solutions. IVD tests are widely used for disease surveillance, hospital infection management, outbreak monitoring, and clinical research. The technology enables healthcare providers to deliver accurate, timely diagnostics, support early intervention, and enhance public health outcomes, making it an essential component of modern infectious disease management.

Global IVD Infectious Diseases Market Drivers

The market drivers for the IVD infectious diseases market can be influenced by various factors. These may include:

Rising Demand for Rapid Diagnostic Testing

The growing need for quick and accurate detection of infectious diseases is driving demand for rapid diagnostic tests in the IVD infectious diseases market. Healthcare providers rely on rapid testing methods to identify infections such as influenza, COVID-19, dengue, and malaria within a short time. These diagnostic tools help clinicians begin treatment sooner and support infection control measures in hospitals and community healthcare settings.

Growing Adoption of Molecular Diagnostic Technologies

Molecular diagnostic technologies are increasingly used for detecting infectious pathogens due to their high sensitivity and accuracy. Techniques such as polymerase chain reaction (PCR) and nucleic acid amplification testing allow laboratories to identify viruses, bacteria, and other pathogens at early stages of infection. Hospitals and diagnostic laboratories are expanding the use of these technologies to improve test accuracy and support disease monitoring programs.

Increasing Focus on Infectious Disease Surveillance

Public health agencies and healthcare organizations are placing greater focus on disease surveillance to monitor outbreaks and control the spread of infections. Diagnostic laboratories and healthcare providers use IVD testing systems to collect data related to infectious disease patterns and transmission. This information supports public health planning, vaccination strategies, and emergency response during outbreaks.

Rising Investment in Diagnostic Research and Development

Pharmaceutical companies, biotechnology firms, and research institutions are increasing investments in diagnostic research aimed at improving infectious disease detection. These efforts include the development of advanced test kits, automated laboratory systems, and multiplex assays capable of detecting multiple pathogens in a single test. Continuous innovation in diagnostic technology supports improvements in testing speed, accuracy, and laboratory efficiency.

Global IVD Infectious Diseases Market Restraints

Several factors act as restraints or challenges for the IVD infectious diseases market. These may include:

High Costs of Diagnostic Equipment and Integration

Developing and implementing advanced IVD systems involves substantial investment in equipment, software, and laboratory integration. Hospitals and laboratories face high procurement costs for automated analyzers, molecular diagnostic platforms, and multiplex testing systems. Additional expenses for staff training, validation, and integration with existing laboratory information systems can limit adoption, particularly among smaller healthcare facilities or in regions with constrained healthcare budgets, slowing overall market expansion.

Regulatory Compliance and Approval Challenges

Compliance with stringent regulatory standards for diagnostic tests can slow market entry and limit product availability. IVD infectious disease products must meet requirements from authorities such as the FDA, CE, and local health agencies, including performance validation and quality control. Lengthy approval timelines, documentation needs, and frequent updates to regulations can increase costs and delay commercialization, posing a barrier for new entrants and smaller diagnostic manufacturers.

Technical Complexity and Laboratory Infrastructure Requirements

Advanced infectious disease diagnostics require specialized laboratory infrastructure, skilled personnel, and precise operational protocols. High-tech molecular assays, automated analyzers, and biosafety procedures demand trained staff and consistent laboratory conditions. Facilities lacking advanced equipment or technical expertise may struggle to adopt these tests efficiently, limiting market penetration in smaller hospitals, remote areas, or developing regions, where infrastructure constraints remain significant.

Reimbursement and Cost Constraints in Healthcare Systems

Limited reimbursement policies and high per-test costs can restrict widespread adoption of IVD infectious disease diagnostics. Healthcare providers may hesitate to implement expensive molecular or multiplex testing without assured insurance coverage or government support. Cost-sensitive markets, especially in developing countries, may prefer traditional testing methods, reducing demand for advanced diagnostic tools and slowing revenue growth for manufacturers in the global IVD infectious diseases market.

Global IVD Infectious Diseases Market Opportunities

The landscape of opportunities within the IVD infectious diseases market is driven by several growth-oriented factors and shifting global demands. These may include:

Rising Demand for Rapid and Accurate Diagnostics

The need for timely detection of infectious diseases is driving demand for rapid diagnostic tests and molecular assays. Hospitals, laboratories, and research institutes are increasingly adopting advanced testing solutions to identify pathogens such as influenza, COVID-19, hepatitis, and HIV. Faster and more precise diagnostics support early treatment decisions, infection control, and improved patient outcomes, boosting adoption of innovative IVD technologies across healthcare facilities globally.

Expansion of Molecular and Point-of-Care Testing

Molecular diagnostics and point-of-care (POC) testing are seeing widespread adoption due to their high sensitivity and convenience. POC platforms allow immediate testing at hospitals, clinics, or remote locations without the need for centralized laboratories. These solutions help reduce turnaround time for infectious disease detection, streamline patient management, and improve public health response to outbreaks, driving growth in the IVD infectious diseases market across multiple end-user segments.

Government Initiatives and Public Health Programs

Increased focus on infectious disease surveillance, outbreak prevention, and vaccination programs is boosting demand for IVD testing. National and regional health authorities support laboratories and hospitals with funding, subsidies, and technical resources for implementing advanced diagnostic tools. Public health initiatives aimed at controlling communicable diseases, such as tuberculosis, malaria, and viral infections, are creating opportunities for manufacturers and service providers to expand their diagnostic testing capabilities in both developed and emerging markets.

Technological Advancements and Automation in Diagnostics

Continuous innovations in laboratory automation, high-throughput analyzers, and multiplex testing are enhancing the efficiency and accuracy of infectious disease diagnostics. Automated platforms reduce manual errors, increase sample processing capacity, and shorten turnaround times. Integration with laboratory information management systems (LIMS) and digital reporting tools further improves workflow efficiency, enabling healthcare facilities to manage larger testing volumes and meet the growing demand for infectious disease diagnostics globally.

Global IVD Infectious Diseases Market Segmentation Analysis

The Global IVD Infectious Diseases Market is segmented based on Product Type, Application, End-User, and Geography.

IVD Infectious Diseases Market, By Product Type

Instruments: The instruments segment holds a major share of the IVD infectious diseases market due to increasing use of automated diagnostic systems in hospitals, diagnostic laboratories, and research centers. These instruments are used to perform tests that detect bacteria, viruses, and other pathogens responsible for infectious diseases. Diagnostic platforms such as PCR analyzers, immunoassay analyzers, and molecular testing systems support fast and accurate detection of infections, helping healthcare providers make timely treatment decisions and manage disease outbreaks effectively.

Reagents: The reagents segment represents a large portion of the market as diagnostic tests require a continuous supply of chemicals, assay kits, and testing materials used during laboratory procedures. Reagents are used in molecular diagnostics, immunoassays, and rapid testing kits to identify infectious agents in blood, urine, or other clinical samples. The increasing demand for infectious disease screening, routine laboratory testing, and large-scale diagnostic programs is driving the use of reagents across healthcare facilities and diagnostic laboratories.

Software: The software segment is expanding steadily as digital systems are increasingly integrated with diagnostic instruments to manage testing workflows and analyze results. Diagnostic software supports laboratory information management, data analysis, and automated reporting of infectious disease test results. Hospitals and laboratories use these platforms to track patient samples, store diagnostic data, and support epidemiological monitoring, improving efficiency and accuracy in infectious disease diagnosis and reporting.

IVD Infectious Diseases Market, By Application

Hepatitis: The hepatitis segment holds a major share of the IVD infectious diseases market due to the high global prevalence of hepatitis B and hepatitis C infections and the need for early detection. In vitro diagnostic tests are widely used to identify viral markers, antibodies, and genetic material associated with hepatitis infections. Hospitals, diagnostic laboratories, and blood banks rely on these tests for screening, disease monitoring, and treatment management to prevent disease progression and transmission.

HIV: The HIV segment represents a significant part of the market as continuous screening and monitoring are required to manage the infection effectively. IVD diagnostic tests such as antibody tests, antigen tests, and nucleic acid tests are used to detect HIV infection at early stages. Public health programs, hospitals, and diagnostic centers conduct routine HIV screening to support early treatment initiation and reduce transmission rates.

Tuberculosis: The tuberculosis segment is expanding steadily due to ongoing global efforts to control and eliminate TB infections. IVD diagnostic solutions including molecular tests, smear microscopy, and culture methods are used to detect Mycobacterium tuberculosis in clinical samples. Governments and healthcare organizations are increasing the use of rapid diagnostic tests to support early identification and treatment of tuberculosis, particularly in high-burden regions.

Influenza: The influenza segment plays an important role in the IVD infectious diseases market as seasonal outbreaks require rapid and accurate diagnosis. Diagnostic tests such as rapid antigen detection tests and molecular assays are used to identify influenza viruses in respiratory samples. Hospitals, clinics, and laboratories depend on these tests to support timely treatment decisions, infection control measures, and monitoring of influenza outbreaks.

IVD Infectious Diseases Market, By End-User

Hospitals: The hospitals segment holds a major share of the IVD infectious diseases market due to the high volume of diagnostic testing performed for patients with suspected infections. Hospitals rely on in vitro diagnostic tools to detect pathogens such as bacteria, viruses, and parasites through methods including molecular testing, immunoassays, and rapid diagnostic kits. These tests support timely clinical decisions, infection control measures, and treatment planning, particularly in emergency departments, inpatient wards, and intensive care units.

Laboratories: The laboratories segment represents a large part of the market as independent diagnostic laboratories and reference labs conduct a wide range of infectious disease tests for healthcare providers. These facilities process large numbers of patient samples using automated analyzers, molecular diagnostics platforms, and high-throughput testing systems. Diagnostic laboratories support hospitals, clinics, and public health agencies by providing accurate test results for diseases such as influenza, tuberculosis, hepatitis, and other infectious conditions.

Academic and Research Institutes: The academic and research institutes segment is expanding steadily as universities, medical research centers, and public health institutes conduct studies related to infectious disease detection and monitoring. These institutions use advanced diagnostic technologies to study pathogen behavior, develop new testing methods, and support epidemiological research. Research organizations also work with healthcare providers and biotechnology companies to improve diagnostic accuracy and strengthen disease surveillance programs.

IVD Infectious Diseases Market, By Geography

North America: North America holds a leading share of the IVD infectious diseases market due to strong healthcare infrastructure, advanced diagnostic laboratories, and high adoption of molecular and rapid diagnostic technologies across the United States and Canada. Hospitals and clinical laboratories widely use in vitro diagnostic systems for the detection of diseases such as influenza, HIV, hepatitis, and respiratory infections. Government disease surveillance programs, high testing volumes, and continuous development of diagnostic technologies support market growth across the region.

Asia Pacific: Asia Pacific is witnessing rapid growth as healthcare systems expand and awareness of early infectious disease detection increases across countries such as China, India, Japan, South Korea, and Australia. Growing population, rising incidence of infectious diseases, and increasing investments in healthcare infrastructure are supporting demand for diagnostic testing. Governments and healthcare organizations across the region are strengthening laboratory networks and adopting advanced diagnostic platforms to improve disease monitoring and outbreak control.

Europe: Europe shows steady growth driven by strong public healthcare systems, advanced research institutions, and well-established diagnostic laboratories across countries such as Germany, the United Kingdom, France, and Italy. Healthcare providers widely use IVD technologies for routine infectious disease screening, hospital infection control, and public health surveillance programs. Regulatory support for diagnostic innovation and growing demand for molecular testing are also supporting market development in the region.

Latin America: Latin America is experiencing gradual growth as healthcare providers and diagnostic laboratories across Brazil, Mexico, and Argentina increase testing capacity for infectious diseases. Rising awareness of early disease detection, improving healthcare infrastructure, and government health initiatives aimed at controlling communicable diseases are contributing to market expansion. Diagnostic laboratories are also adopting modern testing technologies to improve accuracy and reduce testing time.

Middle East & Africa: The Middle East & Africa region records moderate growth supported by expanding healthcare infrastructure and rising focus on infectious disease control in countries such as the UAE, Saudi Arabia, and South Africa. Hospitals and diagnostic laboratories are gradually adopting modern IVD systems to detect diseases such as tuberculosis, malaria, and viral infections. Government health programs and international healthcare collaborations are also contributing to improvements in diagnostic testing capabilities across the region.

Key Players

• The competitive environment is remaining brand-driven, with established players leveraging distribution scale, product breadth, and brand trust. Competitive differentiation is shifting toward material transparency, comfort-led design, and sustainability positioning, while portfolio consolidation and brand acquisition activity are reshaping ownership dynamics.
• Key Players Operating in the Global IVD Infectious Diseases Market
• Abbott Laboratories
• Roche Diagnostics
• Thermo Fisher Scientific
• Danaher Corporation
• Siemens Healthineers
• Becton, Dickinson and Company (BD)
• Hologic, Inc.
• Qiagen N.V.
• Bio-Rad Laboratories
• Cepheid

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 MARKET DEFINITION
• 1.2 MARKET SEGMENTATION
• 1.3 RESEARCH TIMELINES
• 1.4 ASSUMPTIONS
• 1.5 LIMITATIONS

2 RESEARCH METHODOLOGY

• 2.1 DATA MINING
• 2.2 SECONDARY RESEARCH
• 2.3 PRIMARY RESEARCH
• 2.4 SUBJECT MATTER EXPERT ADVICE
• 2.5 QUALITY CHECK
• 2.6 FINAL REVIEW
• 2.7 DATA TRIANGULATION
• 2.8 BOTTOM-UP APPROACH
• 2.9 TOP-DOWN APPROACH
• 2.10 RESEARCH FLOW
• 2.11 DATA AGE GROUPS

3 EXECUTIVE SUMMARY

• 3.1 GLOBAL IVD INFECTIOUS DISEASES MARKET OVERVIEW
• 3.2 GLOBAL IVD INFECTIOUS DISEASES MARKET ESTIMATES AND FORECAST (USD BILLION)
• 3.3 GLOBAL IVD INFECTIOUS DISEASES MARKET ECOLOGY MAPPING
• 3.4 COMPETITIVE ANALYSIS: FUNNEL DIAGRAM
• 3.5 GLOBAL IVD INFECTIOUS DISEASES MARKET ABSOLUTE MARKET OPPORTUNITY
• 3.6 GLOBAL IVD INFECTIOUS DISEASES MARKET ATTRACTIVENESS ANALYSIS, BY REGION
• 3.7 GLOBAL IVD INFECTIOUS DISEASES MARKET ATTRACTIVENESS ANALYSIS, BY PRODUCT TYPE
• 3.8 GLOBAL IVD INFECTIOUS DISEASES MARKET ATTRACTIVENESS ANALYSIS, BY APPLICATION
• 3.9 GLOBAL IVD INFECTIOUS DISEASES MARKET ATTRACTIVENESS ANALYSIS, BY END USER
• 3.10 GLOBAL IVD INFECTIOUS DISEASES MARKET GEOGRAPHICAL ANALYSIS (CAGR %)
• 3.11 GLOBAL IVD INFECTIOUS DISEASES MARKET, BY PRODUCT TYPE (USD BILLION)
• 3.12 GLOBAL IVD INFECTIOUS DISEASES MARKET, BY APPLICATION (USD BILLION)
• 3.13 GLOBAL IVD INFECTIOUS DISEASES MARKET, BY END USER (USD BILLION)
• 3.14 GLOBAL IVD INFECTIOUS DISEASES MARKET, BY GEOGRAPHY (USD BILLION)
• 3.15 FUTURE MARKET OPPORTUNITIES

4 MARKET OUTLOOK

• 4.1 GLOBAL IVD INFECTIOUS DISEASES MARKET EVOLUTION
• 4.2 GLOBAL IVD INFECTIOUS DISEASES MARKET OUTLOOK
• 4.3 MARKET DRIVERS
• 4.4 MARKET RESTRAINTS
• 4.5 MARKET TRENDS
• 4.6 MARKET OPPORTUNITY
• 4.7 PORTER'S FIVE FORCES ANALYSIS
  • 4.7.1 THREAT OF NEW ENTRANTS
  • 4.7.2 BARGAINING POWER OF SUPPLIERS
  • 4.7.3 BARGAINING POWER OF BUYERS
  • 4.7.4 THREAT OF SUBSTITUTE GENDERS
  • 4.7.5 COMPETITIVE RIVALRY OF EXISTING COMPETITORS
• 4.8 VALUE CHAIN ANALYSIS
• 4.9 PRICING ANALYSIS
• 4.10 MACROECONOMIC ANALYSIS

5 MARKET, BY PRODUCT TYPE

• 5.1 OVERVIEW
• 5.2 GLOBAL IVD INFECTIOUS DISEASES MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY PRODUCT TYPE
• 5.3 INSTRUMENTS
• 5.4 REAGENTS
• 5.5 SOFTWARE

6 MARKET, BY APPLICATION

• 6.1 OVERVIEW
• 6.2 GLOBAL IVD INFECTIOUS DISEASES MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY APPLICATION
• 6.3 HEPATITIS
• 6.4 HIV
• 6.5 TUBERCULOSIS
• 6.6 INFLUENZA

7 MARKET, BY END USER

• 7.1 OVERVIEW
• 7.2 GLOBAL IVD INFECTIOUS DISEASES MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY END USER
• 7.3 HOSPITALS
• 7.4 LABORATORIES
• 7.5 ACADEMIC AND RESEARCH INSTITUTES

8 MARKET, BY GEOGRAPHY

• 8.1 OVERVIEW
• 8.2 NORTH AMERICA
  • 8.2.1 U.S.
  • 8.2.2 CANADA
  • 8.2.3 MEXICO
• 8.3 EUROPE
  • 8.3.1 GERMANY
  • 8.3.2 U.K.
  • 8.3.3 FRANCE
  • 8.3.4 ITALY
  • 8.3.5 SPAIN
  • 8.3.6 REST OF EUROPE
• 8.4 ASIA PACIFIC
  • 8.4.1 CHINA
  • 8.4.2 JAPAN
  • 8.4.3 INDIA
  • 8.4.4 REST OF ASIA PACIFIC
• 8.5 LATIN AMERICA
  • 8.5.1 BRAZIL
  • 8.5.2 ARGENTINA
  • 8.5.3 REST OF LATIN AMERICA
• 8.6 MIDDLE EAST AND AFRICA
  • 8.6.1 UAE
  • 8.6.2 SAUDI ARABIA
  • 8.6.3 SOUTH AFRICA
  • 8.6.4 REST OF MIDDLE EAST AND AFRICA

9 COMPETITIVE LANDSCAPE

• 9.1 OVERVIEW
• 9.2 KEY DEVELOPMENT STRATEGIES
• 9.3 COMPANY REGIONAL FOOTPRINT
• 9.4 ACE MATRIX
  • 9.4.1 ACTIVE
  • 9.4.2 CUTTING EDGE
  • 9.4.3 EMERGING
  • 9.4.4 INNOVATORS

10 COMPANY PROFILES

• 10.1 OVERVIEW
• 10.2 ABBOTT LABORATORIES
• 10.3 ROCHE DIAGNOSTICS
• 10.4 THERMO FISHER SCIENTIFIC
• 10.5 DANAHER CORPORATION
• 10.6 SIEMENS HEALTHINEERS
• 10.7 BECTON, DICKINSON AND COMPANY (BD)
• 10.8 HOLOGIC, INC.
• 10.9 QIAGEN N.V.
• 10.10 BIO-RAD LABORATORIES
• 10.11 CEPHEID